Physician profile
Michael Christensen
NPI 1790330454
$1,891.37
in general payments reported to CMS, 2019-2025
30 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $356 · 2022: $579 · 2023: $239 · 2024: $299 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.63 | 2021-2025 | |
| Coloplast Corp | $170.67 | 2022 | |
| Novo Nordisk INC | $125.98 | 2021-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $121.14 | 2022-2024 | Mounjaro |
| Abbott Laboratories | $118.91 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $103.12 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $93.91 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $86.16 | 2022-2025 | Austedo Xr |
| Tris Pharma INC | $63.44 | 2023-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $58.04 | 2021-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $57.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $50.00 | 2022-2023 | |
| Axsome Therapeutics, INC. | $43.66 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $41.90 | 2024-2025 | Inspire |
| Corium, LLC | $39.97 | 2022-2024 | Azstarys |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.79 | 2021-2024 | Gardasil 9, Vaxelis, Capvaxive |
| Mannkind Corporation | $36.38 | 2021 | |
| Boston Scientific Corporation | $35.24 | 2022 | |
| Sanofi Pasteur INC. | $33.90 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $26.76 | 2022-2023 | Quviviq |
| Eisai INC. | $23.05 | 2021 | |
| Astellas Pharma US INC | $21.82 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.67 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.71 | 2025 | Rexulti |
| Hologic Sales and Service, LLC | $18.47 | 2023 | Aptima |
| Biohaven Pharmaceuticals, INC. | $16.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.63 | 2025 | Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $16.04 | 2022 | |
| Alkermes, INC. | $16.00 | 2025 | Aristada, Lybalvi |
| Neurelis, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.